Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft

Horacio E. Adrogue; Liliana Soltero; Geoffrey A. Land; Venkataraman Ramanathan; Luan Truong; Wadi N. Suki

doi:10.1097/01.tp.0000231922.11453.ec

Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft

Horacio E. Adrogue, Liliana Soltero, Geoffrey A. Land, Venkataraman Ramanathan, Luan Truong, Wadi N. Suki

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.

Original language	English (US)
Pages (from-to)	567-569
Number of pages	3
Journal	Transplantation
Volume	82
Issue number	4
DOIs	https://doi.org/10.1097/01.tp.0000231922.11453.ec
State	Published - Aug 2006

Keywords

Antibodies
Graft loss
Humoral rejection
Intravenous immunoglobulin
Plasmapheresis

ASJC Scopus subject areas

Transplantation
Immunology

Access to Document

10.1097/01.tp.0000231922.11453.ec

Cite this

@article{69c8580e8f994acf931b3837f145abfd,

title = "Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft",

abstract = "Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.",

keywords = "Antibodies, Graft loss, Humoral rejection, Intravenous immunoglobulin, Plasmapheresis",

author = "Adrogue, {Horacio E.} and Liliana Soltero and Land, {Geoffrey A.} and Venkataraman Ramanathan and Luan Truong and Suki, {Wadi N.}",

year = "2006",

month = aug,

doi = "10.1097/01.tp.0000231922.11453.ec",

language = "English (US)",

volume = "82",

pages = "567--569",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft

AU - Adrogue, Horacio E.

AU - Soltero, Liliana

AU - Land, Geoffrey A.

AU - Ramanathan, Venkataraman

AU - Truong, Luan

AU - Suki, Wadi N.

PY - 2006/8

Y1 - 2006/8

N2 - Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.

AB - Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.

KW - Antibodies

KW - Graft loss

KW - Humoral rejection

KW - Intravenous immunoglobulin

KW - Plasmapheresis

UR - http://www.scopus.com/inward/record.url?scp=33747888751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747888751&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000231922.11453.ec

DO - 10.1097/01.tp.0000231922.11453.ec

M3 - Article

C2 - 16926602

AN - SCOPUS:33747888751

SN - 0041-1337

VL - 82

SP - 567

EP - 569

JO - Transplantation

JF - Transplantation

IS - 4

ER -

Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this